甲状腺V50是鼻咽癌调强放疗后甲状腺功能减退的危险因素
该回顾性研究纳入206例接受调强放疗的鼻咽癌患者,分析放射性甲状腺功能障碍的危险因素。逻辑回归显示N分期、甲状腺体积和甲状腺V50是甲状腺功能减退的独立预测因子;N分期>1者HT发生率为37.38%,甲状腺V50>24%者HT发生率为54.55%。
要点
- N分期、甲状腺体积和甲状腺V50是鼻咽癌调强放疗后HT的独立预测因子
- N分期>1患者HT发生率37.38%,显著高于N分期≤1者的13.11%
- 甲状腺V50>24%者HT发生率为54.55%,V50≤24%者为34.15%
核心结论
- 甲状腺功能减退的发生与N分期、甲状腺体积和甲状腺V50显著相关。
- 应更多关注甲状腺体积≤12.82 cm3且N分期晚期的鼻咽癌患者。
研究设计与样本
- 回顾性研究,纳入2015年1月至2018年8月在中国科学院大学附属肿瘤医院治疗的206例病理确诊鼻咽癌患者。
- 提取剂量体积直方图数据(平均剂量、绝对体积、V20至V60)作为剂量学参数,建立逻辑回归模型识别2年内发生HT的预测因子。
主要发现
- 有无HT患者间性别、N分期、甲状腺体积、甲状腺平均剂量、甲状腺V20和V50差异显著。
- 逻辑回归分析显示N分期、甲状腺体积和甲状腺V50是HT的独立预测因子。
- 甲状腺体积增大时甲状腺放射敏感性降低。
- N分期>1患者HT发生率37.38%,N分期≤1患者为13.11%。
- 甲状腺V50>24%患者HT发生率为54.55%,甲状腺V50≤24%患者为34.15%。
关键数值与推荐
- N分期>1者HT发生率37.38%,N分期≤1者13.11%。
- 甲状腺V50>24%者HT发生率54.55%,甲状腺V50≤24%者34.15%。
- 甲状腺体积≤12.82 cm3且N分期晚期者需更多关注。
临床怎么用
- 计划设计时关注甲状腺V50,将其作为降低HT风险的剂量学约束参考。
- 对甲状腺体积≤12.82 cm3且N分期晚期的鼻咽癌患者加强甲状腺功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the risk factors of radiation-induced thyroid dysfunction, then combined the clinical factors and optimum thyroid dosimetric parameters to predict the incidence rate of hypothyroidism (HT) and to guide individualized treatment. METHODS: A total of 206 patients with histologically proven nasopharyngeal carcinoma (NPC) treated at the Cancer Hospital of the University of Chinese Academy of Sciences between January 2015 and August 2018 were included. Dose-volume histogram (DVH) data, including mean dose, absolute volume, V20, V25, V30, V35, V40, V45, V50, V55, and V60 were extracted and used as dosimetric parameters. A logistic regression analysis model was built to identify predictors related to HT occurring within 2 years. RESULTS: Sex, N stage, thyroid volume, mean thyroid dose, and thyroid V20 and V50 were significantly different between patients with and without HT. Logistic regression analysis showed that N stage, thyroid volume, and thyroid V50 were independent predictors of HT. The radiosensitivity of the thyroid decreased as the thyroid volume increased. Patients with N stage > 1 had significantly higher HT incidence (37.38%) than patients with N stage ≤1 (13.11%). The incidence of HT was 54.55% in patients with thyroid V50 > 24% and was 34.15% in patients with thyroid V50 ≤ 24%. CONCLUSIONS: The incidence of HT is significantly associated with N stage, thyroid volume, and thyroid V50. More attention should be paid to patients with NPC with thyroid volume ≤ 12.82 cm3 and advanced N stage disease.
引用
- Zhou L, Chen J, Shen W, et al. Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study. Radiat Oncol. 2020. PMID: 32293496. doi:10.1186/s13014-020-01490-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。